FOLFIRINOX induction therapy for stage III pancreatic adenocarcinoma

BACKGROUND: FOLFIRINOX therapy for pancreatic ductal adenocarcinoma (PDAC) has been reported to result in objective response rates that are 2–3 fold higher than other regimens. Our goal was to assess response rates and resection rates in locally unresectable (stage III) patients initially treated wi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Surg Oncol
Main Authors: Sadot, Eran, Doussot, Alexandre, O’Reilly, Eileen M., Lowery, Maeve A., Goodman, Karyn A., Do, Richard Kinh Gian, Tang, Laura H., Gönen, Mithat, D’Angelica, Michael I., DeMatteo, Ronald P., Kingham, T. Peter, Jarnagin, William R., Allen, Peter J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4849545/
https://ncbi.nlm.nih.gov/pubmed/26065868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-015-4647-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados